查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853567

长效避孕药市场按产品类型、最终用户和分销管道划分－2025-2032年全球预测

Long-acting Contraception Market by Product Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，长效避孕药市场规模将达到 64.1 亿美元，复合年增长率为 7.17%。

关键市场统计数据
基准年2024年 36.8亿美元
预计年份：2025年 39.5亿美元
预测年份 2032 64.1亿美元
复合年增长率（%） 7.17%

全面说明长效避孕技术、取得动态以及影响临床和商业性决策的相关人员需求

长效避孕技术凭藉其临床疗效、患者依从性优势以及不断变化的政策重点，已成为全球生殖健康策略的核心组成部分。本文旨在引导读者了解，在现今社会，植入、注射式避孕避孕器和子宫内避孕器不仅是临床选择，更是降低意外怀孕率、增强女性生育自主权的有效工具。文章探讨了技术发展历程、不断变化的给药模式、医保报销压力以及患者期望等因素，这些因素共同塑造了长效避孕技术在临床和零售环境中的应用路径。

从临床证据到市场推广的转变需要专注于生产的灵活性、监管合规性和分销管道的细微差别。植入设计、注射配方和子宫内避孕器材料的创新正在降低推广应用的门槛，但由于供应链分散和供应商能力参差不齐，获取途径仍然存在差异。引言强调，相关人员在规划产品上市、扩大分销规模或建立官民合作关係以扩大可及性并确保永续供应时，必须同时了解临床差异和商业性现实。

技术进步、服务提供方式的创新以及不断变化的监管和报销重点如何再形成采用路径和竞争要务

长效避孕领域正经历快速变革，这受到技术创新、医疗体系转型和社会政治因素的影响。从精密的植入设计、耐受性更佳的皮下注射剂到新一代荷尔蒙子宫内避孕器，器械层面的改善正与数位化医疗工具融合，从而简化病患教育、知情同意和后续追踪流程。同时，医疗服务提供者也不断改进实践，强调任务分担、照护现场植入以及将计划生育服务融入更广泛的基层医疗工作流程。

同时，法规环境和报销框架也在进行调整，以优先考虑准入、安全监测和真实世界证据的产生。远距远端医疗和电子商务管道正在拓展咨询和产品采购的接触点，而区域化生产和策略库存管理等供应链优化措施旨在缩短前置作业时间和降低价格波动。产品差异化需要将临床优势与成熟的分销策略、成本效益和以患者为中心的互动模式相结合，才能实现持续的市场接受度。

评估2025年关税调整如何重塑整个製造和采购生态系统的筹资策略、定价权和供应韧性。

进口关税和改变贸易流向的政策措施会对製造商和医疗保健系统的供应、采购成本和策略采购决策产生显着影响。 2025年美国实施的关税累积效应，透过增加从受影响地区进口的零件和成品的到岸成本，给製造、分销和采购管道带来了新的营运压力。这促使许多製造商重新评估其地理布局，加快关键零件的本地化，并重新调整商业合约价格，以在维持供应承诺的同时保护利润率。

为因应关税影响，医疗采购负责人和公共采购人员强调供应商多元化和多源采购策略。同样，拥有垂直整合能力和区域生产资产的製造商也获得了重新分配库存和稳定供应链的策略自由。重要的是，这些由关税主导的动态正在引发关于长期供应韧性、近岸外包的策略价值以及透明分配成本风险的合约条款必要性的讨论。对于预算有限的临床项目和非营利分销商而言，关税促使他们重新谈判、调整采购优先级，并与製造商加强协调，以确保医疗服务的连续性和公平性取得。

透过连结产品设计、临床交付环境和分销管道的深度细分智能，揭示价值、可及性和接受度之间的交集。

细分市场分析揭示了不同产品类型、终端用户通路和通路的差异化绩效驱动因素和商业重点。依产品类型划分，植入以持续疗效为差异化优势，且植入和取出需要接受密集的临床训练。在植入中，多桿系统和单桿系统之间的差异会影响医疗服务提供者的偏好、库存需求和病患咨询。注射剂需要关注剂量设定和配方特性。肌肉注射和皮下注射在低温运输、给药便利性和使用者接受度方面存在差异。子宫内避孕器呈现两极化的市场动态，含铜子宫内避孕器吸引寻求非荷尔蒙避孕方案的用户，而含激素子宫内避孕器则在出血特性和作用持续时间方面展开竞争。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 人们对具有长达 5 年疗效且副作用较小的药物释放型子宫内系统越来越感兴趣。
  • 开发一种可生物降解的皮下避孕植入，可释放激素长达三年，且易于取出。
  • 远端医疗避孕器植入服务的快速成长缩小了农村和医疗服务不足地区的就医差距
  • 利用先进铜合金和抗发炎表面涂层，在非荷尔蒙、长效子宫内避孕器领域取得创新
  • 长效可逆男性避孕药已获监管部门核准，按需使用血管阻塞凝胶的后期研究取得进展
  • 透过扩大产后避孕植入计画和整合孕产妇健康活动来降低快速再孕率
  • 植入式微晶片技术投资激增，该技术使患者能够远端管理荷尔蒙剂量并追踪用药依从性。
  • 製药公司与非政府组织合作，补贴低收入地区长期避孕药具的分发，并促进其广泛使用。
  • 它专注于使用聚合物基血管内栓塞治疗可逆性男性不孕症，这种栓塞剂有效时间长达六个月，且易于逆转。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 长效避孕药市场（依产品类型划分）

  • 植入
    • 多桿植入
    • 单桿植入
  • 注射
    • 肌肉注射
    • 皮下注射
  • 子宫内避孕器
    • 含铜子宫内避孕器
    • 子宫内激素装置

9. 依最终用户分類的长效避孕药市场

  • 诊所
    • 计划生育诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院

第十章 依分销管道分類的长效避孕药市场

  • 医院药房
  • 在线的
    • 公司网站
    • 第三方平台
  • 零售药局
    • 连锁药局
    • 独立药房

第十一章 各地区长效避孕药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 长效避孕药市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国长效避孕药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bayer AG
    • Organon & Co.
    • CooperCompanies, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc
    • Mayne Pharma Group Limited
    • Sun Pharmaceutical Industries Ltd
    • Lupin Limited
    • Cipla Limited
Product Code: MRR-563BF1FD02BB

The Long-acting Contraception Market is projected to grow by USD 6.41 billion at a CAGR of 7.17% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.68 billion
Estimated Year [2025] USD 3.95 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 7.17%

A comprehensive orientation to long-acting contraceptive technologies, access dynamics, and stakeholder imperatives shaping clinical and commercial decisions

Long-acting contraceptive technologies have become central to reproductive health strategies worldwide, driven by clinical efficacy, patient adherence advantages, and evolving policy priorities. This introduction situates the reader within the contemporary landscape where implants, injectables, and intrauterine devices are not only clinical options but also levers for reducing unintended pregnancy and enhancing reproductive autonomy. The discussion frames technological evolution alongside changing delivery models, reimbursement pressures, and patient expectations that together shape adoption pathways across clinical and retail settings.

Transitioning from clinical evidence to market execution requires attention to manufacturing agility, regulatory alignment, and distribution nuances. Innovations in implant design, injectable formulations, and intrauterine device materials have reduced barriers to uptake, yet access disparities persist due to supply chain fragmentation and heterogeneous provider capabilities. The introduction underscores the imperative for stakeholders to appreciate both clinical differentiators and commercial realities when planning product launches, scaling distribution, or forming public-private partnerships that expand access and ensure sustained supply continuity.

How technological advances, service delivery innovation, and evolving regulatory and reimbursement priorities are reshaping adoption pathways and competitive imperatives

The landscape of long-acting contraception is shifting rapidly under the influence of technological innovation, health-system transformation, and socio-political forces. Device-level improvements-ranging from refined implant architectures and subcutaneous injectables with enhanced tolerability to next-generation hormonal intrauterine options-are converging with digital health tools that streamline patient education, consent, and follow-up. These developments are complemented by evolving provider practices that emphasize task-sharing, point-of-care insertion competencies, and integrated family planning services within broader primary care workflows.

Concurrently, regulatory environments and reimbursement frameworks are adapting to prioritize access, safety surveillance, and real-world evidence generation. Telehealth and e-commerce channels are expanding touchpoints for counseling and product procurement, while supply chain optimization efforts, such as regional manufacturing and strategic inventory management, aim to reduce lead times and price volatility. Together, these transformative shifts are redefining competitive imperatives: product differentiation must now pair clinical advantage with proven distribution strategies, cost efficiency, and patient-centered engagement models to achieve durable adoption.

Assessment of how 2025 tariff changes have reconfigured sourcing strategies, pricing dynamics, and supply resilience across manufacturing and procurement ecosystems

Policy actions that alter import duties and trade flows have a measurable impact on the availability, procurement costs, and strategic sourcing decisions for manufacturers and health systems. The cumulative impact of tariffs introduced in 2025 in the United States has created new operational pressures across manufacturing, distribution, and procurement channels by increasing landed costs for components and finished devices imported from affected geographies. This has led many manufacturers to reassess geographic footprints, accelerate localization of critical components, and reprice commercial contracts to preserve margin while maintaining access commitments.

In response, healthcare purchasers and public buyers have emphasized supplier diversification and multi-sourcing strategies to mitigate tariff exposure. Likewise, manufacturers with vertically integrated capabilities or regional production assets have gained strategic latitude to reallocate inventory and stabilize supply lines. Importantly, these tariff-driven dynamics have intensified conversations about long-term supply resilience, the strategic value of nearshoring, and the need for contractual clauses that transparently allocate cost risk. For clinical programs and non-profit distributors that operate on constrained budgets, the tariffs have prompted renegotiations, procurement prioritization, and closer coordination with manufacturers to ensure treatment continuity and equitable access.

In-depth segmentation intelligence linking product design, clinical delivery settings, and distribution channels to reveal where value, access, and adoption intersect

Segment-level analysis reveals differentiated performance drivers and commercial priorities across product types, end-user channels, and distribution pathways. Based on product type, implants distinguish themselves through sustained efficacy and require focused clinical training for insertion and removal; within implants, the distinctions between multi-rod and single-rod systems influence provider preference, inventory requirements, and patient counseling. Injectables require attention to administration setting and formulation profile; intramuscular versus subcutaneous formats have distinct cold-chain considerations, ease of administration, and acceptability among users. Intrauterine devices present bifurcated dynamics where copper IUDs attract users seeking non-hormonal options while hormonal IUDs compete on bleeding profile and duration of action.

Based on end user, clinics and hospitals exhibit different procurement behaviors and service models. Family planning clinics prioritize cost-effective, high-throughput solutions and community outreach integration, whereas specialty clinics may emphasize advanced counseling and differentiated device portfolios. Private hospitals balance patient expectations and premium services with efficiency, while public hospitals operate under budgetary constraints and broader population health mandates. Based on distribution channel, hospital pharmacies remain central for inpatient and surgical settings; online channels-including company websites and third-party platforms-offer expanded counseling and discreet procurement options; and retail pharmacies, both chain and independent, provide accessible points of care and opportunities for pharmacist-led education. Integrating these segmentation lenses clarifies where clinical value, provider training, reimbursement design, and patient engagement must align to translate product attributes into sustained uptake and equitable access.

Comparative regional analysis showing how regulatory complexity, manufacturing investment, and channel strategies differ across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape regulatory trajectories, manufacturing choices, and channel strategies for long-acting contraception across three macro areas: the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, policy priorities and payer mechanisms vary from public programs in some jurisdictions to private payer-dominated access pathways in others, which influences procurement cadence and commercial contracting approaches. Supply chain nodes in the region are increasingly targeted for local production investments to reduce dependence on transoceanic shipping and tariff exposure, while market access success hinges on demonstration of real-world safety and cost-effectiveness.

In Europe Middle East & Africa, regulatory harmonization efforts coexist with diverse national reimbursement landscapes and infrastructure disparities. This requires adaptive market entry strategies that combine centralized regulatory filings where possible with tailored country-level engagement for public health purchasers and non-governmental providers. Capacity-building initiatives and donor-funded programs often shape demand in lower-resource settings across the region, necessitating affordable, robust devices and simplified service delivery models. In Asia-Pacific, demographic trends, varied health system maturity, and growing domestic manufacturing capabilities create both scale opportunities and competitive intensity. Regional strategies here emphasize cost-efficient production, partnerships with local distributors, and digital-first approaches to patient education and telehealth-enabled counseling. Across all regions, stakeholders must reconcile clinical innovation with pragmatic deployment pathways to ensure sustained access and equitable outcomes.

How corporate strategies centered on clinical evidence, manufacturing scale, and strategic channel partnerships are determining competitive positioning

Company-level behavior in this sector is defined by investments in clinical evidence, manufacturing scale, and distribution partnerships. Leading firms are prioritizing incremental device improvements that enhance patient tolerability and simplify insertion or administration while simultaneously building evidence through post-market surveillance and pragmatic studies. Strategic alliances with contract manufacturers and logistics providers have emerged as a core competency for firms that want to shield operations from trade disruptions and achieve faster time-to-market for new formulations or device variants.

Competition is also playing out through commercial partnerships with clinic networks, hospital systems, and pharmacy chains to secure preferential procurement agreements and integrated training programs for providers. Smaller, specialized entrants are differentiating through niche product design, targeted end-user education, and agile direct-to-consumer engagement via online channels. Meanwhile, larger incumbents leverage broad regulatory expertise to expedite approvals across multiple jurisdictions. Across the competitive landscape, companies that can couple technical innovation with scalable manufacturing, robust clinician training programs, and transparent supply commitments will preserve commercial advantages and deliver predictable access for health systems and patients.

Practical strategic priorities for manufacturers, payers, and providers to secure supply resilience, expand provider capacity, and accelerate patient-centered access

Industry leaders should act decisively to align product development, commercial execution, and access initiatives with evolving system requirements and patient expectations. First, prioritize supply chain diversification and contingency planning that reduce exposure to concentrated supplier nodes and tariff volatility, including nearshoring critical components and establishing backup contract manufacturing relationships. Next, invest in clinical education programs and task-sharing initiatives that reduce insertion barriers and expand provider capacity in family planning clinics, specialty settings, and hospitals alike.

Additionally, firms should harness digital channels to expand counseling and follow-up care, integrating telehealth touchpoints with in-person services to improve adherence and satisfaction. Pricing strategies must be constructed with transparency and flexibility to support public sector procurement while preserving sustainable margins for private sales. Finally, cultivate partnerships with health systems, non-profit organizations, and payers to co-create demonstration programs that generate pragmatic evidence and support reimbursement dialogues. Through these measures, companies can accelerate adoption, secure supply resilience, and expand equitable access while maintaining commercial viability.

Transparent and verifiable research design combining primary clinician and procurement interviews, regulatory evidence, and triangulated secondary sources to ensure methodological rigor

The research underpinning this analysis combined systematic review of peer-reviewed clinical literature, regulatory filings, policy documentation, and primary qualitative inputs to construct a robust evidence base. Primary research included structured interviews with clinicians across family planning clinics, specialty practices, and hospital systems, as well as conversations with procurement leaders, distribution partners, and device manufacturers to validate operational assumptions. Secondary sources provided historical context on device development, regulatory precedents, and public procurement mechanisms, and were triangulated against primary testimony to ensure consistency and reduce bias.

Analytical approaches included cross-segment synthesis to connect product attributes with end-user requirements and channel characteristics, and scenario analysis to explore risk exposures such as trade policy shifts and supply interruptions. Quality assurance processes involved double-coding of interview transcripts, independent methodological review, and sensitivity checks on qualitative inferences. Wherever possible, findings emphasize verifiable clinical endpoints, documented regulatory milestones, and observable procurement behaviors rather than speculative projections, ensuring that conclusions are grounded in replicable evidence and practitioner insights.

Concluding synthesis emphasizing the necessity of coordinated product, supply, and delivery strategies to expand access and realize clinical and commercial value

In conclusion, long-acting contraceptive technologies sit at the intersection of clinical innovation and complex commercial execution. Sustained progress will depend on coordinated efforts that align device development with pragmatic delivery models, resilient manufacturing footprints, and patient-centered engagement strategies. The trajectory ahead favors organizations that can simultaneously demonstrate clinical value, secure strategic supply arrangements, and adapt distribution approaches to local health system realities.

Stakeholders should view the current environment as an opportunity to invest in durable capabilities: robust post-market evidence generation, provider training and task-sharing programs, and partnerships that bridge commercial and public health priorities. By doing so, manufacturers, payers, and providers can expand access, improve health outcomes, and create differentiated, sustainable value propositions across diverse clinical and geographic settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing preference for drug-eluting intrauterine systems with extended efficacy spanning five years and reduced side effects
  • 5.2. Development of biodegradable subcutaneous contraceptive implants providing up to three years of hormone release and simplified removal
  • 5.3. Surge in telemedicine-facilitated IUD insertion services addressing rural and underserved population access gaps
  • 5.4. Innovation in nonhormonal long-acting intrauterine devices using advanced copper alloys and anti-inflammatory surface coatings
  • 5.5. Regulatory approvals for male long-acting reversible contraceptives advancing late-stage trials of on-demand vaso-occlusive gels
  • 5.6. Expansion of postpartum contraceptive implant insertion programs integrated with maternal health initiatives to reduce rapid repeat pregnancies
  • 5.7. Investment surge in implantable microchip technology enabling patient-controlled hormone dosing and remote adherence tracking
  • 5.8. Partnerships between pharmaceutical companies and NGOs to subsidize long-acting contraceptive distribution in low-income regions to boost uptake
  • 5.9. Emphasis on reversible male sterilization with polymer-based intravasal plugs offering six-month efficacy and easy reversibility
  • 5.10. Introduction of extended-duration injectable contraceptives using next-generation progestin formulations with improved metabolic and safety profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Contraception Market, by Product Type

  • 8.1. Implant
    • 8.1.1. Multi-Rod Implant
    • 8.1.2. Single-Rod Implant
  • 8.2. Injectable
    • 8.2.1. Intramuscular Injectable
    • 8.2.2. Subcutaneous Injectable
  • 8.3. Intrauterine Device
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD

9. Long-acting Contraception Market, by End User

  • 9.1. Clinics
    • 9.1.1. Family Planning Clinic
    • 9.1.2. Specialty Clinic
  • 9.2. Hospitals
    • 9.2.1. Private Hospital
    • 9.2.2. Public Hospital

10. Long-acting Contraception Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online
    • 10.2.1. Company Website
    • 10.2.2. Third-Party Platform
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain Pharmacy
    • 10.3.2. Independent Pharmacy

11. Long-acting Contraception Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Long-acting Contraception Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Long-acting Contraception Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Bayer AG
    • 14.3.2. Organon & Co.
    • 14.3.3. CooperCompanies, Inc.
    • 14.3.4. AbbVie Inc.
    • 14.3.5. Teva Pharmaceutical Industries Ltd
    • 14.3.6. Viatris Inc
    • 14.3.7. Mayne Pharma Group Limited
    • 14.3.8. Sun Pharmaceutical Industries Ltd
    • 14.3.9. Lupin Limited
    • 14.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LONG-ACTING CONTRACEPTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2025-203